We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Vectura Group Plc | LSE:VEC | London | Ordinary Share | GB00BKM2MW97 | ORD 0.0271P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 164.80 | 164.80 | 165.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
30/9/2020 10:40 | Is that ‘bull’ as in a load of..... | diesel | |
30/9/2020 10:39 | Exactly - bull! | alexchry | |
30/9/2020 09:54 | Nice buying opportunity for me at these levels, remember the Numis bull case is 250p...... | chrisdgb | |
29/9/2020 19:01 | And there's the problem. Sell the shares, and the court case is won and you miss the rise OR keep the shares and the case is lost and down you go. As I stated earlier it has now become a binary stock based on this single event. Only you can make the decision. | cockneytrader | |
29/9/2020 14:03 | £80 million in the bank and absolutely no vision going forward. You may as well put a chimpanzee in charge and pay it in bananas. | cockneytrader | |
29/9/2020 13:19 | CT - even if approved it will have been nearly four years since getting initial rejection, I should have sold then for 130+ but never expected it to take so long to get resubmission approved and that's by no means certain. The court case is another thing that's dragged on longer than expected, unfortunately, which has not helped the share price | alexchry | |
29/9/2020 11:48 | A1, without significant generic Advair success there can't be much hope for the next generation of generic Ellipta products. The court case is a decision to be made by the appeal court so out of everyone's hands. Diesel, what's changed medium term is that Advair wasn't approved for a second time. That's a pretty fundamental error when you are in the business of generics! | cockneytrader | |
29/9/2020 11:36 | Funny, when it’s rising, it’s worth 200p, when it’s falling its a sell, watch the trend, erratic but it has been rising steadily for 18mnths. See no change in medium term prospects, but I must admit the new management team haven’t yet delivered.... | diesel | |
29/9/2020 11:24 | CT , long term without GSK win and Advair, its SELL, because management statement was for me discouraging - going from big business to 2-3 mil £ business is huge step back down - degeneration IMHP ! Level of the company downgraded ! Very disappointed with new CEO and his no vision ! Hope some one will buy VEC and fire all these rats ! Have a big doubts about capability of Vectura to develop generic Elipta after so many failures with Advair! All league one products are back now in the past time - time of SKP and old Vectura ! Mylan didnt design Advair . Advair designed by Vectura , but Vectura failed until now to get FDA Advair approval and Mylan got it . For me looks like they(Vec) just incapable ! PS Polaris, what is your opinion on Advair multi failure ? | a1ord53 | |
29/9/2020 11:19 | Funds have no more info than you or I - apparently the authorities would be a bit concerned if they did! | aceuk | |
29/9/2020 10:56 | Blackrock buying in should have been a positive here. 5% drop on what news exactly? | justiceforthemany | |
29/9/2020 10:23 | Yes she would have been privy to some confidential matters concerning contracts etc. Very poor judgment on behalf of the Board, which I find a little concerning. | jimboyce | |
29/9/2020 10:10 | What I trying to say is that it's feels like a bit of a gamble. Ask yourself what's the upside on a win vs. a downside on a loss. I would suggest 20% + on a win and 40% (-) on a loss. | cockneytrader | |
29/9/2020 10:06 | It's starting to feel like a binary stock. Win the court case GOOD or lose the court case VERY BAD and all out of our hands. | cockneytrader | |
29/9/2020 09:52 | Out of fire power. Expect these to continue to drift down on no news. Polaris, your 80p entry may yet once again become reality. Will most definitely require Advair approval and court case win in the new year to reach new highs. | cockneytrader | |
29/9/2020 08:43 | Had to put 2 orders in. Anyway, Vectura has plenty of upside potential IMO | peddlers | |
29/9/2020 08:33 | My new broker would only allow me 20,000 shares Must call them as that is hopeless | peddlers | |
29/9/2020 08:21 | Must admit I didn’t realise the connection with Aerami, thought, foolishly, that the new strengthened marketing team had scoured the pharma world for a partner for its shelved VR325 candidate, and then see that a board member is CEO of the new partner. Not impressed! | diesel | |
29/9/2020 08:21 | I think there is high growth potential in this industry. VEC could pull back a bit so I am just about to place a buy order this moring for 40,000 at 98p. | peddlers | |
29/9/2020 07:04 | 10% almost down since entry into FTSE 250 ,modest management update plus Advair delay :( They should continue buy back or pay some divi imo. | a1ord53 | |
29/9/2020 06:41 | Second tranche of buyback completed | gbcol | |
25/9/2020 04:56 | Vectura shortlisted for ’Excellence in Pharma: Contract Services and Outsourcing’ Published:24/09/2020 | taffy100 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions